PLYMOUTH, Minn., Feb. 27 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq:
EVVV) today announced the appointment of Daniel J. Levangie to its Board of
Directors and Audit Committee as an independent director effective as of
February 23, 2007. Mr. Levangie is the President, Surgical Products
Division, and an Executive Vice President and member of the Board of
Directors of Cytyc Corporation, a leading provider of surgical and
diagnostic products targeting women's health and cancer diagnostics.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO )
In addition to his current positions, Mr. Levangie has held several
positions with Cytyc Corporation, including Executive Vice President and
Chief Operating Officer from 2000 to 2006 and Vice President of Commercial
Operations from 1997 to 2000. He also served as Chief Executive Officer and
President of Cytyc Health Corporation from July 2002 to December 2003. Mr.
Levangie has been with Cytyc Corporation since 1992. Mr. Levangie is a
member of the Board of Directors of Dune Medical Devices Ltd., a privately
owned medical device company engaged in the development and
commercialization of devices for real time tissue characterization.
The appointment of Mr. Levangie to ev3's Audit Committee brings ev3
back into compliance with Nasdaq Rule 4350, which stipulates that every
Nasdaq-listed company must have an audit committee with at least three
members, all of whom must be independent under Nasdaq Rule 4200 and
applicable Securities and Exchange Commission rules.
About ev3 Inc.
ev3 is a global medical device company focused on catheter-based
technologies for the endovascular treatment of vascular diseases and
disorders. For more information, please visit http://www.ev3.net .
Statements contained in this press release that are not historical
information are forward-looking statements as defined within the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those projected or implied. Such potential risks and
uncertainties relate, but are not limited to, in no particular order:
product demand and market acceptance, the impact of competitive products
and pricing, and success of clinical testing. More detailed information on
these and additional factors which could affect ev3 Inc.'s operating and
financial results are described in the company's filings with the
Securities and Exchange Commission, including its most recent quarterly
report on Form 10-Q and annual report on Form 10-K. ev3 Inc. urges all
interested parties to read these reports to gain a better understanding of
the many business and other risks that the company faces. Additionally, ev3
Inc. undertakes no obligation to publicly release the results of any
revision to these forward-looking statements, which may be made to reflect
events or circumstances occurring after the date hereof or to reflect the
occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.
and other countries.
SOURCE ev3 Inc.
 back to top
Related links:
http://www.ev3.net
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
INVESTOR RELATIONS CONTACTS, Patrick
Spangler, CFO of ev3 Inc., +1-763-398-7000, pspangler@ev3.net ;
or Marian Briggs, +1-612-455-1742, mbriggs@psbpr.com , or Nancy
Johnson, +1-612-455-1745, njohnson@psbpr.com , both of Padilla
Speer Beardsley
|
